var data={"title":"Oxacillin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxacillin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6691?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">see &quot;Oxacillin: Drug information&quot;</a> and <a href=\"topic.htm?path=oxacillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxacillin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452679\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bactocill in Dextrose</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049081\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin (Antistaphylococcal)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444086\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection (nonmeningitis)</b> (Bradley 2018; <i>Red Book</i> [AAP 2015])<b>:</b> IM, IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body</b> <b>Weight</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal</b> <b>Age</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">37.5 mg/kg/dose every 6 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">37.5 mg/kg/dose every 6 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg/dose every 6 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">37.5 mg/kg/dose every 6 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis</b> (Bradley 2018): IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body</b> <b>Weight</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal</b> <b>Age</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 6 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">29 to 60 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 6 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;8 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 6 hours</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049074\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">see &quot;Oxacillin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection </b>(<i>Red Book</i> [AAP 2015])<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: Infants, Children, and Adolescents: IM, IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: Infants, Children, and Adolescents: IM, IV: 150 to 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g</b>/<b>day </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment</b>: Children and Adolescents: IV: 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for at least 4 weeks; longer durations may be necessary; may use in combination with gentamicin for some resistant organisms (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis/Ventriculitis:</b> Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b> (IDSA [Tunkel 2004]; IDSA [Tunkel 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (CAP) moderate to severe infection, <i>S. aureus</i> (methicillin-susceptible):</b> Infants &gt;3 months, Children, and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections</b> (IDSA [Stevens 2014])<b>:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA): IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Necrotizing infection due to MSSA: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day;</b> continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: IM, IV: 250 to 500 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: IM, IV: 1,000 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment: Methicillin-susceptible Staphylococcus aureus (MSSA) (AHA [Baddour 2015]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Native valve: 12 g/day in 4 or 6 divided doses (ie, 2,000 mg every 4 hours or 3,000 mg every 6 hours) for 6 weeks. <b>Note:</b> Dosing intended for <i><b>complicated</b></i>right-sided infective endocarditis (IE) or left-sided IE. For <i><b>uncomplicated</b></i>right-sided IE, 2 weeks of therapy may be adequate</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prosthetic valve: 12 g/day in 6 divided doses (ie, 2,000 mg every 4 hours) for at least 6 weeks (use with rifampin for entire course and gentamicin for first 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections (IDSA [Stevens 2014]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Due to methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA): IV: 1,000 to 2,000 mg every 4 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Necrotizing infection due to MSSA: IV: 1,000 to 2,000 mg every 4 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical site infections (trunk or extremity [away from axilla or perineum]):</b> IV: 2,000 mg every 6 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Not dialyzable (0% to 5%). There are no dosage adjustments provided in the manufacturer's labeling; however, manufacturer suggests considering a reduction in total dosage if renal impairment is known or suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204167\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactocill in Dextrose: 1 g/50 mL (50 mL); 2 g/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204151\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049084\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer by deep IM injection into a large muscle mass (eg, gluteus maximus); avoid sciatic nerve injury </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Direct IV injection: Administer over 10 minutes at a concentration of 100 mg/mL  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent IV infusion: Administer over 15 to 30 minutes (Klaus 1989); extending the infusion over 60 minutes has been used for peripheral administration by some ambulatory centers to decrease the risk of phlebitis in homecare patients (Dahlgren 1997) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204186\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Premixed infusions: Store in a freezer at -20&deg;C (4&deg;F). Thaw at room temperature or under refrigeration only. Thawed bags are stable for 21 days under refrigeration or 48 hours at room temperature. Do not refreeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Vials: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); refer to manufacturer&rsquo;s labeling for specific storage instructions after dilution (varies by concentration and diluent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049083\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of bacterial infections, such as osteomyelitis, septicemia, endocarditis, and CNS infections, due to susceptible penicillinase-producing strains of <i>Staphylococcus</i> (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204221\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia, leukopenia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Serum sickness-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute interstitial nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204174\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to oxacillin, any penicillin, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204155\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in patients with histories of significant allergies and/or asthma; discontinue treatment and institute appropriate therapy if an allergic reaction occurs</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatitis: Acute hepatitis and reversible elevations of serum transaminases have been reported sometimes accompanied by rash and leukopenia; onset after 2 to 3 weeks of therapy; monitor periodically throughout therapy (Dahlgren 1997; Faden 2009; Maraqa 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: May contain a significant amount of sodium; consult product specific labeling for amount. The elderly population may respond with a blunted natriuresis to salt loading. This may be clinically important in diseases such as congestive heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neonates: Use with caution in neonates; elimination of drug is decreased; dosage adjustment is needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26019922\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates, elimination rate is decreased due to immature renal function; dosage adjustment is needed; hematuria and azotemia have occurred in neonates and infants receiving high-dose oxacillin. In a study of pediatric patients (5 to 19 years) receiving outpatient oxacillin, significantly less rash was reported in the nafcillin group (10.3%) compared to the oxacillin group (31.7%) (Maraqa 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299797\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204160\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12663&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Oxacillin is distributed into the amniotic fluid and is detected in cord blood. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049080\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic CBC with differential, urinalysis, BUN, serum creatinine, AST and ALT; number and type of stools/day for diarrhea; observe IV site for extravasation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204154\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204173\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Into bile, amniotic, and pleural fluids; insignificant concentrations in CSF and aqueous humor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~94% (mainly albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (PNA: 8 to 15 days): 1.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &le;2 years: 0.9 to 1.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 20 to 30 minutes; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 30 minutes; IV: 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and bile (unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049088\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">May contain a significant amount of sodium; consult product specific labeling for amount.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323563\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bactocill in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $17.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (50 mL): $24.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Oxacillin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $17.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $33.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $138.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038712\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biotam (VN);</li>\n      <li>Bristopen (FR);</li>\n      <li>Cloxacap (SG);</li>\n      <li>Cloxcin (SG);</li>\n      <li>Minzil (PH);</li>\n      <li>Ocillina (TW);</li>\n      <li>Ocina (VN);</li>\n      <li>Oxacilina (CO);</li>\n      <li>Oxacillin (PL);</li>\n      <li>Oxan (PH);</li>\n      <li>Oxanon (BR);</li>\n      <li>Oxapen (PH);</li>\n      <li>Oxatalis (PH);</li>\n      <li>Penstapho (BE, IT);</li>\n      <li>Procillin (KR);</li>\n      <li>Prostafilina (VE);</li>\n      <li>Prostaphlin (CZ, EE, HN);</li>\n      <li>Stapenor (AT);</li>\n      <li>Syntarpen (PL);</li>\n      <li>Wydox (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/7396459/pubmed\" target=\"_blank\" id=\"7396459\">7396459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett ED, Cantey JB, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 24th ed. American Academy of Pediatrics; 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dahlgren AF, &quot;Adverse Drug Reactions in Home Care Patients Receiving Nafcillin or Oxacillin,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(10):1176-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/9161625/pubmed\" target=\"_blank\" id=\"9161625\">9161625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faden D and Faden HS, &quot;The High Rate of Adverse Drug Events in Children Receiving Prolonged Outpatient Parenteral Antibiotic Therapy for Osteomyelitis,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(6):539-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/19483522/pubmed\" target=\"_blank\" id=\"19483522\">19483522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maraqa NF, Gomez MM, Rathore MH, et al, &quot;Higher Occurrence of Hepatotoxicity and Rash in Patients Treated With Oxacillin, Compared With Those Treated With Nafcillin and Other Commonly Used Antimicrobials,&quot; <i>Clin Infect Dis</i>, 2002, 34(1):50-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/11731945/pubmed\" target=\"_blank\" id=\"11731945\">11731945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olans RN and Weiner LB, &quot;Reversible Oxacillin Hepatotoxicity,&quot; <i>J Pediatr</i>, 1976, 89(5):835-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/978335/pubmed\" target=\"_blank\" id=\"978335\">978335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxacillin for injection [prescribing information]. Dayton, NJ: AuroMedics Pharma LLC; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxacillin [prescribing information]. Princeton, NJ: Sandoz Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson DC, Cookson TL, and Grisafe JA, &quot;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&quot; <i>Drug Intell Clin Pharm</i>, 1987, 21(12):985-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/3428165/pubmed\" target=\"_blank\" id=\"3428165\">3428165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-pediatric-drug-information/abstract-text/28203777/pubmed\" target=\"_blank\" id=\"28203777\">28203777</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12663 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452679\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049081\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444086\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049074\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204167\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F204151\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049084\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F204186\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049083\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204221\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204174\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204155\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26019922\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299797\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204160\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049080\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204154\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F204173\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1049088\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323563\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038712\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12663|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">Oxacillin: Drug information</a></li><li><a href=\"topic.htm?path=oxacillin-patient-drug-information\" class=\"drug drug_patient\">Oxacillin: Patient drug information</a></li></ul></div></div>","javascript":null}